Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1420-9071
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients ; day:28 ; month:6 ; year:2019 ; pages:1-13
Cellular and molecular life sciences ; (28.6.2019), 1-13
- Urheber
-
Keup, Corinna
Benyaa, Karim
Hauch, Siegfried
Sprenger-Haussels, Markus
Tewes, Mitra
Mach, Pawel
Bittner, Ann-Kathrin
Kimmig, Rainer
Hahn, Peter
Kasimir-Bauer, Sabine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00018-019-03189-z
- URN
-
urn:nbn:de:101:1-2019102315555244634568
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Keup, Corinna
- Benyaa, Karim
- Hauch, Siegfried
- Sprenger-Haussels, Markus
- Tewes, Mitra
- Mach, Pawel
- Bittner, Ann-Kathrin
- Kimmig, Rainer
- Hahn, Peter
- Kasimir-Bauer, Sabine
- SpringerLink (Online service)
Ähnliche Objekte (12)
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Rat Models of Hormone Receptor-Positive Breast Cancer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort